Swedish Orphan Biovitrum
303,6 SEK -0,65%4 investorer følger denne virksomhed
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Omsætning
22,12 mia.
EBIT %
18,38 %
P/E
40,64
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
SOBI
Daglig lav / høj pris
302,8 / 311
SEK
Markedsværdi
108,08 mia. SEK
Aktieomsætning
152,77 mio. SEK
Volumen
502 t
Finanskalender
Delårsrapport
24.10.2024
Årsrapport
05.02.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Investor | 34,7 % | 34,7 % |
| Morgan Stanley Smith Barney | 9,9 % | 9,9 % |
| Fjärde AP-fonden | 5,9 % | 5,9 % |
| State Street Bank and Trust | 4,3 % | 4,3 % |
| AMF - Försäkring Och Fonder | 4,0 % | 4,0 % |
| JP Morgan Chase Bank NA | 3,4 % | 3,4 % |
| Northern Trust Company, London Branch | 3,2 % | 3,2 % |
| Swedbank Robur fonder | 2,7 % | 2,7 % |
| Handelsbanken Fonder | 2,3 % | 2,3 % |
| BNY Mellon Na (Former Mellon), W9 | 1,7 % | 1,7 % |
ViserAlle indholdstyper
Swedish Orphan Biovitrum AB: Sobi® and Enable Injections announce agreement to develop and distribute Aspaveli® in combination with enFuse® in Sobi territories
Swedish Orphan Biovitrum AB: Sobi has completed issues of class C shares
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools